Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSIW) Non-Current Debt (2024 - 2025)

TriSalus Life Sciences' Non-Current Debt history spans 2 years, with the latest figure at $33.0 million for Q4 2025.

  • For Q4 2025, Non-Current Debt rose 49.64% year-over-year to $33.0 million; the TTM value through Dec 2025 reached $33.0 million, up 49.64%, while the annual FY2025 figure was $33.0 million, 49.64% up from the prior year.
  • Non-Current Debt reached $33.0 million in Q4 2025 per TLSIW's latest filing, up from $32.8 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $33.0 million in Q4 2025 to a low of $21.3 million in Q2 2024.